138 related articles for article (PubMed ID: 27810078)
1. Can Carbohydrate Antigen-125 Be a New Biomarker to Guide Heart Failure Treatment?: The CHANCE-HF Trial.
D'Aloia A; Vizzardi E; Metra M
JACC Heart Fail; 2016 Nov; 4(11):844-846. PubMed ID: 27810078
[No Abstract] [Full Text] [Related]
2. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review.
Núñez J; de la Espriella R; Miñana G; Santas E; Llácer P; Núñez E; Palau P; Bodí V; Chorro FJ; Sanchis J; Lupón J; Bayés-Genís A
Eur J Heart Fail; 2021 Sep; 23(9):1445-1457. PubMed ID: 34241936
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate antigen 125: a new biomarker in heart failure.
Vizzardi E; D'Aloia A; Curnis A; Dei Cas L
Cardiol Rev; 2013; 21(1):23-6. PubMed ID: 22735832
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
Núñez J; Llàcer P; Bertomeu-González V; Bosch MJ; Merlos P; García-Blas S; Montagud V; Bodí V; Bertomeu-Martínez V; Pedrosa V; Mendizábal A; Cordero A; Gallego J; Palau P; Miñana G; Santas E; Morell S; Llàcer A; Chorro FJ; Sanchis J; Fácila L;
JACC Heart Fail; 2016 Nov; 4(11):833-843. PubMed ID: 27522630
[TBL] [Abstract][Full Text] [Related]
5. Value of BNP and tumour marker CA125 in patients with heart failure.
Chen YX; Wang XQ; Fang CF; Wang JF; Tang LJ
Acta Cardiol; 2008 Aug; 63(4):501-6. PubMed ID: 18795589
[TBL] [Abstract][Full Text] [Related]
6. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure.
Núñez J; Sanchis J; Bodí V; Fonarow GC; Núñez E; Bertomeu-González V; Miñana G; Consuegra L; Bosch MJ; Carratalá A; Chorro FJ; Llàcer A
Eur Heart J; 2010 Jul; 31(14):1752-63. PubMed ID: 20501480
[TBL] [Abstract][Full Text] [Related]
7. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure.
Núñez J; Núñez E; Bayés-Genís A; Fonarow GC; Miñana G; Bodí V; Pascual-Figal D; Santas E; Garcia-Blas S; Chorro FJ; Rizopoulos D; Sanchis J
Eur Heart J Acute Cardiovasc Care; 2017 Dec; 6(8):685-696. PubMed ID: 27199489
[TBL] [Abstract][Full Text] [Related]
8. Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.
Núñez J; Merlos P; Fácila L; Llàcer P; Bosch MJ; Bertomeu-Martínez V; García-Blas S; Montagud V; Pedrosa V; Mendizábal A; Cordero A; Miñana G; Sanchis J; Bertomeu-González V;
Rev Esp Cardiol (Engl Ed); 2015 Feb; 68(2):121-8. PubMed ID: 25623430
[TBL] [Abstract][Full Text] [Related]
9. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion.
Huang F; Zhang K; Chen J; Cai Q; Liu X; Wang T; Lv Z; Wang J; Huang H
Clin Biochem; 2013 Nov; 46(16-17):1694-700. PubMed ID: 24060730
[TBL] [Abstract][Full Text] [Related]
10. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement.
Antonini-Canterin F; Popescu BA; Popescu AC; Beladan CC; Korcova R; Piazza R; Cappelletti P; Rubin D; Cassin M; Faggiano P; Nicolosi GL
Int J Cardiol; 2008 Aug; 128(3):406-12. PubMed ID: 17662495
[TBL] [Abstract][Full Text] [Related]
11. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure.
Núñez J; Núñez E; Sanchis J; Bodí V; Fonarow GC; Miñana G; Palau P; Bertomeu-González V; Carratalá A; Mainar L; Chorro FJ; Llàcer A
Int J Cardiol; 2012 Aug; 159(1):21-8. PubMed ID: 21367474
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate antigen 125 in heart failure. New era in the monitoring and control of treatment.
Llàcer P; Bayés-Genís A; Núñez J
Med Clin (Barc); 2019 Apr; 152(7):266-273. PubMed ID: 30442374
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of antigen carbohydrate 125 in heart failure.
Núñez J; Miñana G; Núñez E; Chorro FJ; Bodí V; Sanchis J
Heart Fail Rev; 2014 Sep; 19(5):575-84. PubMed ID: 23925386
[TBL] [Abstract][Full Text] [Related]
14. Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation.
Karaca O; Guler GB; Guler E; Gunes HM; Alizade E; Agus HZ; Gol G; Kahveci G; Esen O; Esen AM; Turkmen M
Congest Heart Fail; 2012; 18(3):144-50. PubMed ID: 22587744
[TBL] [Abstract][Full Text] [Related]
15. [CA-125 - does this next biomarker have a chance to hope for an expectation of risk stratification in patients with heart failure?].
Zieliński T
Kardiol Pol; 2010 Jul; 68(7):779-80. PubMed ID: 20648435
[No Abstract] [Full Text] [Related]
16. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies.
Zhuang J; Faggiano P; Li Q; Pradelli D; Med V; Peng W; Zuo M; Xu Y
J Cardiovasc Med (Hagerstown); 2014 Dec; 15(12):864-72. PubMed ID: 25353973
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and diagnostics in heart failure.
Gaggin HK; Januzzi JL
Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of carbohydrate antigen 125 in heart failure.
Santas E; Palau P; Bayés-Ge A; Núñez J
Biomark Med; 2020 Mar; 14(4):249-252. PubMed ID: 32125176
[No Abstract] [Full Text] [Related]
19. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
20. Combining echo and natriuretic peptides to guide heart failure care in the outpatient setting: A position paper.
Dini FL; Carluccio E; Montecucco F; Rosa GM; Fontanive P
Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29044493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
